News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aptalis Pharmaceutical Technologies Sponsors American Association of Pharmaceutical Scientists Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism at AAPS Annual Meeting and Exposition



10/11/2012 3:31:16 PM

Bridgewater, New Jersey, October 11, 2012 – Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition October 14 – 18, 2012 in Chicago, Illinois. The 2012 annual meeting and exposition is an international forum for the exchange of knowledge among an expected 9,000 attendees, including scientists working in drug design, discovery, development, delivery, packaging, scale- up, clinical trials, and regulatory sciences.

AAPS Research Achievement Awards

The AAPS Research Achievement Awards are intended to recognize outstanding scientists who have conducted fundamental research that has had significant impact in the fields of Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM). Aptalis Pharmaceutical Technologies is the sponsor of the 2012 awards being presented during AAPS’ annual meeting and exposition October 14–18 in Chicago. PPDM is the section of the American Association of Pharmaceutical Scientists that provides an opportunity for the presentation of new data and an exchange of ideas by individuals actively engaged in the various facets of pharmacokinetics, pharmacodynamics, drug metabolism, transport, biopharmaceutics, and related sciences.

Aptalis APPS Poster Presentation and Recruitment

Meeting participants are invited to visit the Aptalis Pharmaceutical Technologies’ poster presentation: T2132, “Development of orally disintegrating tablets comprising controlled- release multiparticulate beads.” P.J. Stevens, G. Venkatesh, J. Lai, October 16, 2012, Hall F, McCormick Place 9:30 a.m. to 12:30 p.m. and to visit the Aptalis Career Center Booth # CC1.

About Aptalis Pharmaceutical Technologies

Aptalis Pharmaceutical Technologies, formerly known as Eurand Pharmaceutical Technologies, offers a broad portfolio of oral drug delivery technology platforms: Customized Drug Release, Bioavailability Enhancement, and Taste Masking for ODT’s (orally disintegrating tablets) and other dosage forms. Together, these technology platforms combined with licensing, manufacturing, and R&D capabilities enable Aptalis Pharmaceutical Technologies to produce customized drug formulation solutions for partners across a range of dosage forms and therapies with high patient acceptability. Aptalis Pharmaceutical Technologies develops and manufactures products for its partners, as well as supports the drug development process for the Aptalis Pharma pipeline and portfolio of products. For more information about Aptalis Pharmaceutical Technologies, visit www.AptalisPharmaTech.com

About Aptalis

Aptalis Pharma Inc. is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. Aptalis, formed from the recent combination of Axcan Pharma and Eurand, has manufacturing and commercial operations in the United States, the European Union and Canada, and its products include ZENPEP®, CANASA®, CARAFATE®, PYLERA®, LACTEOL®, DELURSAN®, PANZYTRAT® and SALOFALK®. Aptalis also formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary technology platforms including bioavailability enhancement of poorly soluble drugs, custom release profiles, and taste-masking/orally disintegrating tablet (ODT) formulations. For more information, visit www.aptalispharma.com.

Media Contact:

Erin O’Brien, Director of Marketing

Aptalis Pharmaceutical Technologies

908-927-9600, Ext. 4084

eobrien@aptalispharma.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES